200 related articles for article (PubMed ID: 21792197)
61. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
[TBL] [Abstract][Full Text] [Related]
62. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
Onal C; Torun N; Guler OC; Yildirim BA
Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
[TBL] [Abstract][Full Text] [Related]
63. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
64. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
[TBL] [Abstract][Full Text] [Related]
65. Post-treatment FDG PET-CT in head and neck carcinoma: comparative analysis of 4 qualitative interpretative criteria in a large patient cohort.
Zhong J; Sundersingh M; Dyker K; Currie S; Vaidyanathan S; Prestwich R; Scarsbrook A
Sci Rep; 2020 Mar; 10(1):4086. PubMed ID: 32139722
[TBL] [Abstract][Full Text] [Related]
66. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
Abelson JA; Murphy JD; Trakul N; Bazan JG; Maxim PG; Graves EE; Quon A; Le QT; Diehn M; Loo BW
Lung Cancer; 2012 Dec; 78(3):219-24. PubMed ID: 23009727
[TBL] [Abstract][Full Text] [Related]
67. Training and external validation of pre-treatment FDG PET-CT-based models for outcome prediction in anal squamous cell carcinoma.
Frood R; Mercer J; Brown P; Appelt A; Mistry H; Kochhar R; Scarsbrook A
Eur Radiol; 2024 May; 34(5):3194-3204. PubMed ID: 37924344
[TBL] [Abstract][Full Text] [Related]
68. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Parlak C; Topkan E; Onal C; Reyhan M; Selek U
Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
[TBL] [Abstract][Full Text] [Related]
69. Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
Chang S; Koo PJ; Kwak JJ; Kim SJ
Oncology; 2016; 90(2):97-102. PubMed ID: 26771676
[TBL] [Abstract][Full Text] [Related]
70. Application of sequential (18)F-FDG PET/CT scans for concurrent chemoradiotherapy of non-surgical squamous cell esophageal carcinoma.
Li Y; Lin Q; Wang L; Sun L; Dai M; Luo Z; Zheng H; Zhao L; Wu H
J BUON; 2014; 19(2):517-23. PubMed ID: 24965415
[TBL] [Abstract][Full Text] [Related]
71. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
[TBL] [Abstract][Full Text] [Related]
72. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
[TBL] [Abstract][Full Text] [Related]
73. Role of positron emission tomography-computed tomography in the management of anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
[TBL] [Abstract][Full Text] [Related]
74. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
75. Value of Intratumoral Metabolic Heterogeneity and Quantitative
Pinho DF; King B; Xi Y; Albuquerque K; Lea J; Subramaniam RM
AJR Am J Roentgenol; 2020 Apr; 214(4):908-916. PubMed ID: 32069078
[No Abstract] [Full Text] [Related]
76. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.
Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E
Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335
[TBL] [Abstract][Full Text] [Related]
77. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
78. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
79. Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
Iagaru A; Kundu R; Jadvar H; Nagle D
Hell J Nucl Med; 2009; 12(1):26-9. PubMed ID: 19330178
[TBL] [Abstract][Full Text] [Related]
80. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
